PRESS RELEASE Lund, 2 February 2011
EXINI Diagnostics AB, listed on AktieTorget, has been very positively received in Germany, and is thus increasing its sales investment on this market. EXINI recently sold and delivered installations of EXINI brain™ and EXINI dat™ to Klinik Dr. Hancken GmbH in Stade − the company's seventh delivery on the German market. Above all, EXINI sees a big opportunity in working with the private hospitals, where there is a great demand for efficiency- and safety-increasing products. During the first six months of 2011 German-speaking staff from EXINI will be doing dedicated work on the German market.
Since the introduction on the German market EXINI has sold a total of seven systems to three clinics. The systems included are: EXINI heart™, EXINI brain™, EXINI dat™ and EXINI bone™. The company now has good customer references in Kiel, Mainz and Stadde. During 2011 EXINI is thus increasing its investment by introducing German-speaking sales staff on the end-customer market in parallel with preparation of distributor establishment.
The CEO, Magnus Aurell, comments:
- "We have long been active in Europe, and signed a distribution contract for Great Britain as recently as in November. It is extremely positive that the German market has now taken off. We have hitherto delivered directly to our German customers, but are now starting preparations for finding distributors so as to rationalise the sales process and meet the demand on Europe's biggest market. The high proportion of private hospitals makes Germany a particularly interesting market for EXINI, which offers quality- and efficiency-increasing products."
Germany is the single biggest market in Europe, with about 1,200 nuclear-medicine departments (the corresponding figure for the Nordic countries is about 80 wards). By way of comparison, Japan, with its approx. 1,300 wards, is the world's second biggest nuclear-medicine market. On the Japanese market, EXINI recently concluded an exclusive contract with FUJIFILM Pharma Co Ltd regarding EXINI Bone™, giving EXINI a guaranteed value of SEK 15m and a potential maximum value of SEK 24m over a three-year period.
For further information please contact:
Magnus Aurell, CEO
Tel.: +46 (0)46-286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB
EXINI Diagnostics AB offers advanced solutions for support in medical decision-making to hospitals worldwide. The system is based on advanced image analysis through artificial intelligence, and can independently interpret X-ray images and make diagnostic proposals. The system is used in this way as decision-making support for the diagnosing physician. EXINI is working on products for diagnosis of some of the most widespread diseases, e.g. coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Prof. Lars Edenbrandt, and now has 12 employees. EXINI is listed on AktieTorget, and has about 250 shareholders. The main owner is Bo Håkansson.
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 17, SE-223 70 Lund, Sweden Tel.: +46 (0)46 286 54 20, Fax: +46 (0)46 286 54 29, info@exini.com, www.exini.com, VAT No.: SE556576199501